1. Home
  2. NKTR

NKTR

Nektar Therapeutics

Logo Nektar Therapeutics

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Founded: N/A Country:
United States
United States
Employees: N/A City: SAN FRANCISCO
Market Cap: 227.7M IPO Year: 1994
Target Price: $3.50 AVG Volume (30 days): 2.5M
Analyst Decision: Hold Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.45 EPS Growth: N/A
52 Week Low/High: $0.41 - $1.75 Next Earning Date: 05-07-2024
Revenue: $90,122,000 Revenue Growth: -2.10%
Revenue Growth (this year): -23.6% Revenue Growth (next year): -7.76%

Share on Social Networks: